Takeda formerly Nicomed Russia - CIS Nycomed Takeda

History

2023: Appointment of Yulia Chetverikova as CEO

In mid-May 2023, it became known about the appointment of Yulia Chetverikova to the post of general director of the Russian representative office of Takeda. In this position, she replaced Elena Kartasheva, who headed the company since 2019. Kartasheva was appointed head of the union of TuRC countries (Turkey, Russia, Belarus, Kazakhstan) in Takeda, whose headquarters are located in Istanbul. Read more here.

2016: Start of deliveries to Belarus and Uzbekistan

In 2016, the company began supplying products to the Republic of Belarus and the Republic of Uzbekistan.

2013: Plant launch in Yaroslavl for 75 million euros

Takeda Russia was one of the first foreign pharmaceutical companies to build their own plant in the Russian Federation in Yaroslavl. The construction of the plant was completed in 2012, and commercial production was launched in 2013. The total investment for the period from 2010 to 2018 amounted to 98.9 million euros, including 75 million euros for the construction of the plant. The capacity of the plant allows the production of 90 million sterile ampoules and more than 3 billion tablets per year.

2011: Takeda Pharmaceutical acquires Nycomed for €9.6 billion

In September 2011, Takeda Pharmaceutical acquired the Swiss company Nycomed for €9.6 billion.

2010

NYCOMED is a private international pharmaceutical company with a differentiated portfolio of products based on branded drugs used in gastroenterology, antiprostudal and anti-inflammatory drugs, cardiology, neurology, osteoporosis prevention and surgery. A wide range of over-the-counter products complements the company's portfolio.

As of July 2010, NYCOMED employs 12,000 people worldwide, its products are available in more than 100 countries. The company has a reliable position in Europe and in fast-growing markets such as Russia-CIS and Latin America. The sale of the company's products in the United States and Japan is carried out through partnership agreements with other companies.

It was headquartered in Zurich, Switzerland. The company had global sales of 3.4 billion euros in 2008 and adjusted EBITDA of 1.2 billion euros.

At this time, the company presents original and innovative drugs in Russia, as well as branded "generics" both of its own production and on exclusive partnership agreements with other pharmaceutical companies. NYCOMED is one of the leaders in the supply of drugs for areas of medicine such as neurology (cerebrovascular diseases), osteoporosis, cardiology, endocrinology, pain management, etc.

1993: Swiss Nycomed enters the Russian market

NYCOMED has been operating on the Russian market since 1993. The company's products have been known to Russian doctors since the mid-1980s, since NYCOMED supplied significant volumes of medicines to the USSR.

Notes